Predictors of recurrence in surgical stage II endometrial adenocarcinoma

被引:35
作者
Feltmate, CM
Duska, LR
Chang, YC
Flynn, CE
Nikrui, N
Kiggundu, E
Goodman, A
Fuller, AF
McIntyre, JF
机构
[1] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
关键词
D O I
10.1006/gyno.1999.5380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. A retrospective review of surgical stage II endometrial carcinoma was performed to evaluate clinical course, treatment, recurrence rate, and survival. Methods, A list of patients with clinical and surgical stage II endometrial carcinoma was obtained through the tumor registry and from the pathology department from 1988 to 1996. Data were collected on all cases of patients with endometrial carcinoma meeting stage II criteria by FIGO surgical staging, Variables including stage, histology, grade, lymph vascular space invasion (LVI), type and extent of surgery, radiation type and amount, smoking, menstrual status, parity, and age were evaluated for their predictive ability of disease recurrence. Cox proportional hazard regression models were used to examine the potential predictors of time to relapse univariately and multivariately. Results. Of patients identified, 65 underwent primary surgical staging. Only adenocarcinomas were included. Mean follow-up time was 4.7 years (range 0.2-9.6 years), Postoperative radiation was given to 85.7% of patients. There were 10 patients (15.4%) with recurrence of disease with a mean time to recurrence of 25 months. Five-year disease-specific survival was 93%, The only significant predictor of time to relapse was LVI (P = 0.002) in the multivariate analysis, Conclusion. This retrospective review suggests that primary surgery followed by postoperative radiation therapy gives excellent results in surgical stage II disease, LVI appears to be a strong predictor of disease recurrence regardless of postoperative radiation therapy. It is difficult to draw conclusions about the type and amount of radiation given because recurrence rate is so low; however, it is reasonable to continue adjuvant radiation especially in cases where LVI is identified. (C) 1999 Academic Press.
引用
收藏
页码:407 / 411
页数:5
相关论文
共 13 条
[1]  
AALDERS J, 1980, OBSTET GYNECOL, V56, P419
[2]   RISK-FACTORS AND PROGNOSIS IN STAGE II ENDOMETRIAL CANCER [J].
BERMAN, ML ;
AFRIDI, MA ;
KANBOUR, AI ;
BALL, HG .
GYNECOLOGIC ONCOLOGY, 1982, 14 (01) :49-61
[3]   PROGNOSTIC FACTORS AND LONG-TERM SURVIVAL IN ENDOMETRIAL ADENOCARCINOMA WITH CERVICAL INVOLVEMENT [J].
BOENTE, MP ;
YORDAN, EL ;
MCINTOSH, DG ;
GRENDYS, EC ;
ORANDI, YA ;
DAVIES, S ;
BECK, D ;
GRAHAM, JE ;
MILLER, A ;
MARSHALL, R ;
DOLAN, T ;
KIRSCHNER, C ;
REDDY, S ;
WILBANKS, GD .
GYNECOLOGIC ONCOLOGY, 1993, 51 (03) :316-322
[4]  
HOMESLEY HD, 1977, OBSTET GYNECOL, V49, P604
[5]  
KADAR N, 1992, OBSTET GYNECOL, V80, P655
[6]   ENDOMETRIAL ADENOCARCINOMA WITH CLINICAL-EVIDENCE OF CERVICAL INVOLVEMENT - ACCURACY OF DIAGNOSTIC PROCEDURES, CLINICAL COURSE, AND PROGNOSTIC FACTORS [J].
LEMINEN, A ;
FORSS, M ;
LEHTOVIRTA, P .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1995, 74 (01) :61-66
[7]  
MONTZ FJ, 1988, OPER TECH GYNECOL SU, V3, P61
[8]   RELATIONSHIP BETWEEN SURGICAL PATHOLOGICAL RISK-FACTORS AND OUTCOME IN CLINICAL STAGE-I AND STAGE-II CARCINOMA OF THE ENDOMETRIUM - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
MORROW, CP ;
BUNDY, BN ;
KURMAN, RJ ;
CREASMAN, WT ;
HELLER, P ;
HOMESLEY, HD ;
GRAHAM, JE .
GYNECOLOGIC ONCOLOGY, 1991, 40 (01) :55-65
[9]   ENDOMETRIAL CARCINOMA WITH CERVICAL INVOLVEMENT (STAGE-II) - PROGNOSTIC FACTORS AND VALUE OF COMBINED RADIOLOGICAL-SURGICAL TREATMENT [J].
ONSRUD, M ;
AALDERS, J ;
ABELER, V ;
TAYLOR, P .
GYNECOLOGIC ONCOLOGY, 1982, 13 (01) :76-86
[10]   MANAGEMENT OF ENDOMETRIAL ADENOCARCINOMA WITH CERVICAL INVOLVEMENT [J].
RUBIN, SC ;
HOSKINS, WJ ;
SAIGO, PE ;
NORI, D ;
MYCHALCZAK, B ;
CHAPMAN, D ;
LEWIS, JL .
GYNECOLOGIC ONCOLOGY, 1992, 45 (03) :294-298